FFA
GLUE icon

Farther Finance Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

Farther Finance Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.61K Buy
315
+17
+6% +$321 ﹤0.01% 4589
2026
Q1 		$5.12K Sell
298
-141
-32% -$2.7K ﹤0.01% 4480
2025
Q4 		$6.88K Buy
+439
New +$5.92K ﹤0.01% 4148

Other funds holding GLUE

ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM
MFA
Mayflower Financial Advisors Boston, Massachusetts $1.16B AUM 24.36% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Farther Finance Advisors's GLUE Position: Q2 2026 in Review

Farther Finance Advisors increased its Monte Rosa Therapeutics (GLUE) stake by 5.7% in Q2 2026, buying an estimated $321 and bringing the position to 315 shares worth $7.61K. The position accounts for ﹤0.01% of the portfolio, ranked #4589.

Farther Finance Advisors first reported a position in GLUE in Q4 2025 and has held it in 3 quarters since. 23 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Farther Finance Advisors held 315 shares of Monte Rosa Therapeutics worth $7.61K as of Q2 2026.
  • Farther Finance Advisors bought 17 Monte Rosa Therapeutics shares in Q2 2026, an estimated $321.
  • Monte Rosa Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #4589 holding.
  • Farther Finance Advisors first reported a position in Monte Rosa Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 23 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.